MIMEDX is involved in the development and marketing of placental tissue products for use in healthcare, specifically in advanced wound care and surgical solutions. The company provides various products aimed at enhancing patient healing.

MIMEDX

MiMedx | 29,714 followers on LinkedIn. MIMEDX is a pioneer and leader in the field of placental tissue. With more than a decade of helping clinicians manage chronic and hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical settings of healthcare. The Company&#39;s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.

Retired Regional Sales Director at MiMedx

Lee Terrell

Daniel Merlin

Susan Settle

Don Curtis

MiMedx

Want to optimize patient care while cutting costs? MIMEDX’s 5 Medicare Big Data Claims reviews prove it’s possible. Discover how our products are reshaping the landscape of wound care, one successful outcome at a time: https://bit.ly/41mNpLw #MIMEDX #HealthcareEfficiency #WoundCare #Medicare

We just wrapped up another successful Summit focused on hot topics in wound care and reimbursement in Las Vegas, NV! A huge thank you to our amazing speakers who brought their expertise and passion to the stage. Kathleen Schaum, MS, President and Founder of Kathleen D. Schaum & Associates, Inc., shared her invaluable insights as a wound/ulcer management reimbursement strategy consultant and educator. Vickie Driver, DPM, MS, FACFAS, a renowned podiatric surgeon, also delivered an inspiring session that informed and motivated us all. Don't miss out on the last chance to attend our final summit of 2024! Secure your spot now and be part of the conversation: https://lnkd.in/eAk7niKt #MIMEDX #MedicalEducation #Reimbursement #WoundCare #Podiatry #SkinSubstitutes

Is delayed healing putting your patients at risk of an amputation? RCT outcomes have shown patients who received MIMEDX's Dehydrated Human Amnion/Chorion Membrane (DHACM) allografts had 2x to 3.8x faster wound closure in DFUs compared with the Standard of Care (SOC).¹⁻²* For VLUs, DHACM recipients had 60% more wound closure than the SOC at 16 weeks.³^ Learn more: https://bit.ly/41mNpLw

In Mohs Surgery, placental-based allografts can be used for MMS defects when patients are not good candidates for traditional methods of autologous tissue reconstruction. Dr. Vij, a Dermatologic Surgeon, shares when he chooses to use EPIFIX. Watch the full video: https://bit.ly/3GJf4Nb #MIMEDX #EPIFIX #MohsSurgery

Join the MIMEDX leadership team’s live webcast and discussion of our Q3 2024 operating and financial results this afternoon. Click the link to review the results and webcast details: https://lnkd.in/ePUuSfEd

Our CDI services at WoundGenex can help you: • Enhance patient care: By ensuring accurate and complete documentation, we can improve the quality of care provided to patients. • Boost revenue: Accurate documentation is essential for maximizing reimbursement and reducing denials. • Mitigate risk: By ensuring compliance with industry standards, we can help protect your practice from audits and penalties. Let WoundGenex help you elevate your clinical documentation and achieve your practice goals. #CDI #PatientCare #WoundGenex #EliteGraft #RecoveryBoost #WoundHealing #MedicalInnovation #AdvancedTherapy #HealingJourney #HealthcareTechnology

WoundGenex

With MIMEDX’s wide variety of allograft configurations, wound care clinicians can choose the product that best meets their treatment objectives. Learn more about our portfolio of the #1 most studied human placental allografts: https://bit.ly/3YgoCYk #MIMEDX #WoundCare #Wounds #SkinSubstitutes

Check out this inspiring article featured in The New York Times highlighting the vast clinical potential of placental tissue, the importance of placenta donation, and how products like our placental allografts have made a difference for patients facing challenging wounds. It is so rewarding to see our patients with the opportunity to tell their stories and thrive! https://lnkd.in/eYVR7_u3

With only one application, Dr. Bhatia observed closure using EPIEFFECT® as a protective barrier as part of the treatment protocol to support the healing cascade and to aid in the development of granulation tissue. Dr. Bhatia chose EPIEFFECT for this post-Mohs dorsal hand defect with an exposed tendon. This allowed Dr. Bhatia to abstain from splinting the patient’s hand. This obviated the need for physical therapy after closure. Human placental allografts provide an advanced alternative for patients who are not ideal candidates for traditional methods of reconstruction post-Mohs surgery. Learn more about the use of EPIEFFECT in Mohs Surgery: https://bit.ly/43gUC0G #MIMEDX #EPIEFFECT #Dermatology #MohsSurgery

No matter how the landscape evolves, MIMEDX remains your unwavering partner to support you, your practice, and your therapy decisions. Learn more about our support systems tailored for your practice: https://bit.ly/41mNpLw #MIMEDX #SkinSubstitutes #WoundCare #Medicare #LCDs

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

COM:MIMEDX

MIMEDX

Last Close

7.64

12/11 21:00

Market Cap

1.01B

Beta: -

Volume Today

529.35K

Avg: -

Analysis Not Available